{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T21:03:28Z","timestamp":1778965408190,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"am","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.neurol.2022.09.001","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T18:11:37Z","timestamp":1667499097000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of hereditary amyotrophic lateral sclerosis"],"prefix":"10.1016","volume":"179","author":[{"given":"P.","family":"Corcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S.","family":"Piegay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Vourc\u2019h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2022.09.001_bib0245","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S1474-4422(21)00465-8","article-title":"Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis","volume":"21","author":"Goutman","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nn.3584","article-title":"State of play in amyotrophic lateral sclerosis genetics","volume":"17","author":"Renton","year":"2014","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurol.2022.09.001_bib0255","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1212\/WNL.5.3.182","article-title":"Epidemiologic investigations of amyotrophic lateral sclerosis. 2. Familialaggregations indicative of dominant inheritance. I","volume":"5","author":"Kurland","year":"1955","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.09.001_bib0260","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1212\/WNL.5.4.249","article-title":"Epidemiologic investigations of amyotrophic lateral sclerosis. 2. Familiar aggregations indicative of dominant inheritance. II","volume":"5","author":"Kurland","year":"1955","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.09.001_bib0265","first-page":"172","article-title":"Recherches sur une maladie non encore d\u00e9crite du syst\u00e8me musculaire (atrophie musculaire progressive)","volume":"24","author":"Aran","year":"1850","journal-title":"Arch Gen M\u00e9decine"},{"key":"10.1016\/j.neurol.2022.09.001_bib0270","first-page":"316","article-title":"On hereditary in progressive muscular atrophy as illustrated in the FARR family of Vermont","volume":"4","author":"Osler","year":"1880","journal-title":"Arch of Med"},{"key":"10.1016\/j.neurol.2022.09.001_bib0275","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(21)00414-2","article-title":"Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis","volume":"21","author":"Goutman","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0280","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1212\/WNL.0000000000002773","article-title":"Presymptomatic ALS genetic counseling and testing: Experience and recommendations","volume":"86","author":"Benatar","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.09.001_bib0285","first-page":"59","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with I amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"N Eng J Med"},{"key":"10.1016\/j.neurol.2022.09.001_bib0290","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrneurol.2011.150","article-title":"Clinical genetics of amyotrophic lateral sclerosis: what do we really know?","volume":"7","author":"Andersen","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0295","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jnnp-2020-325064","article-title":"Effect of clustering in the genetic screening of 235 French ALS families","volume":"92","author":"Corcia","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.neurol.2022.09.001_bib0300","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0022-510X(99)00022-2","article-title":"Genetics of I ALS and consequences for diagnosis. French ALS Research Group","volume":"165","author":"Camu","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2022.09.001_bib0305","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS:Riluzole study group","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Eng J Med"},{"key":"10.1016\/j.neurol.2022.09.001_bib0310","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of Edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomized double-blind, placebo controlled trial","volume":"16","author":"Writing Group","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0315","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.09.001_bib0320","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.neurol.2020.12.003","article-title":"Therapeutic news in ALS","volume":"177","author":"Corcia","year":"2021","journal-title":"Rev Neurol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0325","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/WCO.0000000000000594","article-title":"Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis","volume":"31","author":"Ly","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0330","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/j.ymthe.2021.04.008","article-title":"Gene therapy for ALS: a review","volume":"29","author":"Amado","year":"2021","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.neurol.2022.09.001_bib0335","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.3390\/ijms20184388","article-title":"Gene therapy for ALS-A perspective","volume":"20","author":"Cappella","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurol.2022.09.001_bib0340","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.09.001_bib0345","series-title":"Results from the Phase 3 VALOR study and its open-label extension: evaluating the clinical efficacy and safety of Tofersen in adults with ALS and confirmed SOD1 mutation","author":"Miller","year":"2021"},{"key":"10.1016\/j.neurol.2022.09.001_bib0350","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/WCO.0000000000000984","article-title":"Therapeutic strategies for C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia","volume":"34","author":"Hautbergue","year":"2021","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2022.09.001_bib0355","doi-asserted-by":"crossref","first-page":"a024224","DOI":"10.1101\/cshperspect.a024224","article-title":"Disease Mechanisms of C9ORF72 Repeat Expansions","volume":"8","author":"Gendron","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.neurol.2022.09.001_bib0360","doi-asserted-by":"crossref","first-page":"18591","DOI":"10.1073\/pnas.2005748117","article-title":"Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS\/FTD mice","volume":"117","author":"Zu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2022.09.001_bib0365","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","article-title":"Suppression of mutant C9orf72 expression by a potent mixed blackbone antisense oligonucleotide","volume":"28","author":"Tran","year":"2022","journal-title":"Nat Medecine"},{"key":"10.1016\/j.neurol.2022.09.001_bib0370","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.omtn.2022.04.007","article-title":"Preclinical evaluation of WVE-004, an investigational stereopure oligonucleotide for the treatment of C9orf72 -associated ALS or FTD","volume":"28","author":"Liu","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.neurol.2022.09.001_bib0375","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis","volume":"28","author":"Korobeynikov","year":"2022","journal-title":"Nat Medecine"},{"key":"10.1016\/j.neurol.2022.09.001_bib0380","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature09320","article-title":"Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS","volume":"466","author":"Elden","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.neurol.2022.09.001_bib0385","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.molmed.2013.09.001","article-title":"Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?","volume":"20","author":"van den Heuvel","year":"2014","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.neurol.2022.09.001_bib0390","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.21147","article-title":"Pathological TDP-43 distinguishes sporadic Amyotrophic Lateral Sclerosis from Amyotrophic Lateral Sclerosis with SOD1 Mutations","volume":"61","author":"MacKenzie","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0395","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and microRNA in familiar ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2022.09.001_bib0400","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.neurol.2022.09.001_bib0405","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.neuron.2013.07.033","article-title":"Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis","volume":"79","author":"Ling","year":"2013","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.neurol.2022.09.001_bib0410","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004960","article-title":"Randomized, double-blind, placebo-controlled trial of Arimoclomol in rapidly progressive SOD1 ALS","volume":"90","author":"Benatar","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.09.001_bib0415","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ana.24950","article-title":"Pyrimethamine significantly lowers cerebrospinal fluid Cu\/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations","volume":"81","author":"Lange","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0420","doi-asserted-by":"crossref","first-page":"102270","DOI":"10.1016\/j.pneurobio.2022.102270","article-title":"Amyloid \u03b2, Tau, and \u03b1-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases","volume":"214","author":"Sengupta","year":"2022","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0425","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ana.23668","article-title":"A novel monoclonal antibody reveals a conformational alteration shared by amyotrophic lateral sclerosis-linked SOD1 mutants","volume":"72","author":"Fujisawa","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0430","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14728222.2020.1738390","article-title":"Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS)","volume":"24","author":"Abati","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.neurol.2022.09.001_bib0435","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1172\/JCI123931","article-title":"Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology","volume":"129","author":"Pozzi","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurol.2022.09.001_bib0440","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.neuron.2019.11.007","article-title":"Antibody Therapy Targeting RAN Proteins Rescues C9 ALS\/FTD Phenotypes in C9orf72 Mouse Model","volume":"105","author":"Nguyen","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.neurol.2022.09.001_bib0445","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/brain\/awab472","article-title":"The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis","volume":"145","author":"Salmon","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2022.09.001_bib0450","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/practneurol-2021-002989","article-title":"Genetic testing in motor neurone disease","volume":"22","author":"Dharmadasa","year":"2022","journal-title":"Pract Neurol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0455","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ana.25276","article-title":"Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion","volume":"84","author":"Benatar","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2022.09.001_bib0460","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/brain\/awab404","article-title":"Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases","volume":"145","author":"Benatar","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2022.09.001_bib0465","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000516752","article-title":"Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants","volume":"55","author":"Brown","year":"2021","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.neurol.2022.09.001_bib0470","article-title":"Design of a randomized, placebo-controlled, phase 3 trial of Tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study","author":"Benatar","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2022.09.001_bib0475","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3233\/JND-200531","article-title":"Beyond the traditional clinical trials for amyotrophic lateral sclerosiss and the future impact of gene therapy","volume":"8","author":"Cappella","year":"2022","journal-title":"J Neuromusc Dis"},{"key":"10.1016\/j.neurol.2022.09.001_bib0480","article-title":"Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis","author":"McCann","year":"2020","journal-title":"J Med Genet"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722007895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722007895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:46:15Z","timestamp":1758519975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378722007895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":48,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0035378722007895"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.09.001","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of hereditary amyotrophic lateral sclerosis","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}